Use of reboxetine to treat narcolepsy
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
1 . A method of reducing the number of inadvertent naps in a human being having narcolepsy with cataplexy, comprising administering from 5 mg to 10 mg of reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, daily for at least two weeks to a human being in need thereof, wherein the human being is experiencing narcolepsy with cataplexy, wherein the human being is selected for having experienced at least 7 cataplexy attacks in the week before the human being first received reboxetine, wherein during the second week that reboxetine is administered, the human being experiences at least 20% fewer inadvertent naps per week as compared to the week before the human being first received reboxetine.
2 . The method of claim 1 , wherein 5 mg of reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered once a day.
3 . The method of claim 1 , wherein reboxetine, or a pharmaceutically acceptable salt thereof, is administered in a dosage form further containing a polymer.
4 . The method of claim 1 , wherein reboxetine, or a pharmaceutically acceptable salt thereof, is administered in a dosage form further containing a binder.
5 . The method of claim 1 , wherein reboxetine, or a pharmaceutically acceptable salt thereof, is administered in a dosage form further containing a lubricant.
6 . The method of claim 1 , wherein reboxetine, or a pharmaceutically acceptable salt thereof, is administered in a dosage form further containing a diluent.
7 . The method of claim 1 , wherein reboxetine, or a pharmaceutically acceptable salt thereof, is administered in a dosage form further containing a disintegrant.
8 . The method of claim 1 , wherein 5 mg of the reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered twice a day to the human being for a first week.
9 . The method of claim 8 , wherein 5 mg of the reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered to the human being in the morning and 5 mg of the reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered to the human being in the afternoon.
10 . The method of claim 1 , wherein 6 mg to 7 mg of a pharmaceutically acceptable salt of reboxetine is administered to the human being in the morning and 6 mg to 7 mg of a pharmaceutically acceptable salt of reboxetine is administered to the human being in the afternoon.
11 . The method of claim 1 , wherein 6 mg to 7 mg of the pharmaceutically acceptable salt of reboxetine is administered to the human being in the morning.
12 . The method of claim 2 , wherein the 5 mg of the reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered to the human being once daily for a first week.
13 . The method of claim 1 , wherein 5 mg of the reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered to the human being once daily for a first week, and
wherein 5 mg of the reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered to the human being in the morning and 5 mg of the reboxetine, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, is administered to the human being in the afternoon for a second week.
14 . The method of claim 1 , wherein the human being has a diagnosis of narcolepsy with cataplexy that meets International Classification of Sleep Disorders, Third Edition criteria.
15 . The method of claim 1 , wherein the human being has an Epworth Sleepiness Scale score that is greater than 10 prior to receiving the reboxetine.
16 . The method of claim 1 , wherein the reboxetine is in a pharmaceutically acceptable salt form.